Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Sarah Cannon
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
30.0%
+2.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NeutralThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
MD Anderson Cancer Center
Competitor Displacement Rate
10.0%
Competitors are displacing Sarah Cannon in 10.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: While strong, Sarah Cannon faces competition from centers with broader clinical trial offerings and higher specialized research visibility.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[cancer.org][clinicaltrials.gov]⚠️ Identified Vulnerability:Clinical Trials
Primary Threat Identified:MD Anderson Cancer Center
Target Persona:Oncology Researchers
🚨 Threat Velocity:3/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)